Abstract: Sotuletinib (BLZ945) is a highly selective, brain-penetrant small molecule inhibitor of the colony-stimulating factor 1 receptor (CSF-1R), currently being investigated for its therapeutic potential in solid tumors. By targeting the tumor microenvironment (TME), BLZ945 disrupts the critical signaling pathways that regulate tumor-associated macrophages (TAMs). Interestingly, its effects are highly tissue- and context-dependent. In breast and cervical carcinoma models, BLZ945 attenuates the rapid turnover and recruitment of TAMs, leading to their depletion and a subsequent increase in anti-tumor CD8+ T cell infiltration. Conversely, in glioblastoma multiforme (GBM), BLZ945 does not deplete TAMs due to the presence of glioma-secreted survival factors; instead, it "re-educates" them by downregulating M2-like pro-tumorigenic markers and enhancing phagocytosis. Through these distinct mechanisms, BLZ945 effectively halts tumor progression, regresses established tumors, and significantly improves survival in preclinical models, highlighting its promise as a microenvironment-targeted anticancer therapy.
1. Introduction
The tumor microenvironment (TME) plays a critical role in cancer progression, invasion, and immune evasion. Among the non-cancerous stromal cells within the TME, tumor-associated macrophages (TAMs) are particularly prominent. High TAM density is frequently correlated with high tumor grade and poor prognosis in various malignancies, including breast, cervical, and prostate carcinomas, as well as gliomas [1][2]. TAMs often adopt an alternatively activated, or "M2-like," regulatory phenotype characterized by the expression of markers such as IL-10, CD206, and MHC class II molecules, which promote immunosuppression and tumor growth [1].
The colony-stimulating factor 1 (CSF-1) and its cognate receptor (CSF-1R) form a signaling axis that is essential for the recruitment, differentiation, and survival of macrophages [1]. Sotuletinib (BLZ945) is a highly selective, brain-penetrant small molecule inhibitor of CSF-1R kinase activity. By pharmacologically blocking CSF-1R signaling, BLZ945 targets the TAM population within the TME, offering a novel therapeutic strategy that shifts the focus from directly targeting genetically unstable cancer cells to modulating the genetically stable stromal compartment [1][2].
2. Pharmacological Activity
BLZ945 exhibits potent and highly specific pharmacological activity against CSF-1R. Biochemically, it demonstrates an IC50 of 1 nM for CSF-1R, which is more than 3,200-fold higher than its affinity for other kinases. For instance, its affinity for PDGFR-alpha is approximately 10,000-fold lower than for CSF-1R, ensuring that its in vivo therapeutic effects are driven specifically by CSF-1R inhibition rather than off-target kinase inhibition [2]. Furthermore, BLZ945 is brain-penetrant, making it highly suitable for central nervous system malignancies [2].
In preclinical in vivo models, BLZ945 has demonstrated remarkable efficacy across multiple solid tumors. In the PDGF-B-driven glioma (PDG) mouse model, which recapitulates human proneural GBM, BLZ945 halted glioma growth, induced regression of established large tumors, and significantly improved long-term, symptom-free survival [2]. It also slowed the intracranial growth of patient-derived proneural GBM tumor spheres and cell line xenografts [2]. In peripheral solid tumors, BLZ945 treatment significantly decreased primary tumor growth in the MMTV-PyMT transgenic mouse model of mammary carcinogenesis and abrogated tumor growth in the K14-HPV-16 transgenic model of estrogen-dependent cervical cancer [1].
3. Molecular Mechanism of Action
The molecular mechanism of BLZ945 is uniquely dependent on the specific tumor microenvironment, manifesting either as TAM depletion or TAM re-education.
In breast and cervical carcinomas, CSF-1R signaling is required to maintain a rapid turnover of TAMs, which recirculate in and out of neoplastic lesions within a span of about 5 days [1]. BLZ945 administration obstructs the de novo recruitment of macrophages from the host and depletes existing TAMs in the tumor and surrounding stroma. This depletion is tissue-specific, affecting tumors and liver Kupffer cells, but not circulating monocytes or lung macrophages [1]. Crucially, the reduction in TAMs coincides with a significant increase in the infiltration of CD8+ cytotoxic T cells into the tumors, thereby relieving TAM-mediated immunosuppression and altering the CD8+ to CD4+ T cell ratio in favor of anti-tumor immunity [1].
Conversely, in the glioma microenvironment, BLZ945 does not deplete TAMs. Glioma cells secrete survival factors—specifically GM-CSF, IFN-gamma, and CXCL10—that protect TAMs from BLZ945-induced apoptosis [2]. Instead of dying, the surviving TAMs are "re-educated." BLZ945 downregulates a specific set of M2-associated genes (including Mrc1/CD206, Arg1, Adm, and Serpinb2), blunting their tumor-promoting functions and significantly enhancing their phagocytic capacity [2]. Furthermore, BLZ945 abrogates heterotypic paracrine signaling between macrophages and glioma cells, specifically preventing macrophage-induced phosphorylation of Akt in glioma cells, which leads to reduced glioma cell proliferation and increased apoptosis [2].
4. Structure-Activity Relationship (SAR)
While comprehensive structural derivatives and traditional structure-activity relationship (SAR) data are not detailed in the provided literature, the physicochemical and structural optimization of BLZ945 has yielded two critical properties for its efficacy. First, it achieves extreme target selectivity, with an IC50 of 1 nM for CSF-1R and a >3,200-fold selectivity window over other kinases, effectively eliminating off-target toxicities associated with broader tyrosine kinase inhibitors (such as PDGFR inhibition) [2]. Second, its structure allows it to readily cross the blood-brain barrier, a vital characteristic that enables its potent activity against intracranial malignancies like glioblastoma [2].
5. Current Limitations
Despite its potent anti-tumor effects, BLZ945 therapy has several limitations. First, macrophage depletion in peripheral tumors is incomplete; a residual population of TAMs (accounting for less than 1% of total tumor cells) remains even after continuous treatment [1]. Second, the effects of BLZ945 are highly reversible. In mammary tumor models, TAM populations completely recover to baseline levels within 3 days of halting BLZ945 treatment, indicating that continuous administration is essential to maintain therapeutic efficacy [1]. Third, while BLZ945 decreases primary mammary tumor growth, it does not significantly affect the density, size, or cumulative burden of pulmonary metastases in the MMTV-PyMT model [1]. Finally, the presence of TME-derived survival factors (like GM-CSF and IFN-gamma) in certain cancers, such as GBM, completely prevents TAM depletion, necessitating a reliance on phenotypic re-education rather than cellular clearance [2].
6. Future Perspectives
The unique ability of BLZ945 to re-educate TAMs rather than merely depleting them opens new avenues for microenvironment-targeted therapies. Because myeloid cells can blunt the response to chemotherapy and promote re-vascularization following radiation, future clinical strategies should explore combining CSF-1R inhibitors like BLZ945 with standard glioma-directed therapies (e.g., irradiation or chemotherapy) to achieve synergistic effects [2]. Additionally, the discovery of a "minimal gene signature" (comprising genes like Adm, Arg1, F13a1, Mrc1, and Serpinb2) associated with BLZ945 treatment has translational value. This signature successfully predicts a significant survival advantage in patients with proneural GBM, independent of total macrophage numbers [2]. This suggests that future diagnostic and therapeutic efforts should focus on evaluating and modulating the specific phenotype of TAMs within the tumor, rather than solely quantifying their presence.
